Authors
Latest:
Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DOThe neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]
Latest:
Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MDThe professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]
Latest:
College Checklist for People Living With MigraineTransition to college life poses unique challenges for students living with migraine, and a comprehensive checklist helps ensure they are prepared for this critical phase.
Latest:
NeuroVoices: Anne Marie Morse, DO, FAASM, on the Impact of the Once-Nightly Sodium Oxybate Approval for Pediatric NarcolepsyThe director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.
Latest:
Treatment Options and Outcomes of Cervical Artery Dissection in Adults: Eytan Raz, MD, PhDThe neurointerventional radiologist at NYU Langone provided clarity on the individualized treatment options for cervical artery dissection following a scientific statement paper from the American Heart Association. [WATCH TIME: 7 minutes]
Latest:
American Heart Association Statement Stresses Need for Comprehensive Post-Stroke CareThe collaborative newly published statement stressed the need to address gaps in care that may lead to high risk of stroke recurrence.
Latest:
Expanding the Migraine Treatment Protocol Beyond CGRPs: Emad Estemalik, MDThe director of the headache section at Cleveland Clinic detailed some of the emerging nonpharmacological preventive methods for migraine, as well as where research is headed following the explosion of CGRP-targeting therapies. [WATCH TIME: 6 minutes]
Latest:
Mechanistic Potential of Synapse-Targeted Agent ALX-001 for Alzheimer Disease: Adam Mecca, MD, PhDThe associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
Latest:
Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhDThe assistant professor at the University of South Florida provided perspective on the influence of circadian rhythm in neurocognitive health and the possibilities of screening for circadian rhythm issues for large-scale clinical trials. [WATCH TIME: 4 minutes]
Latest:
Early Intervention and Disease Prevention With a Novel Epigenome Approach: Boris Kantor, PhDThe associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]
Latest:
Pridopidine’s Impact on ALS, Assessing Results From HEALEY ALS Platform Trial: Melanie Leitner, PhDThe consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
Latest:
AUPN Leadership Minute Episode 29: Transitioning From Chair to VP and DeanEpisode 29 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Allison Brashear MD, MBA, of University at Buffalo. [WATCH TIME: 5 minutes]
Latest:
Additive Potential of BTK Inhibitors in Multiple Sclerosis Treatment Paradigm: Diana Gallagher, MDThe head of Biogen’s MS and Immunology Department Unit detailed the potential of combination approaches to treat MS, including the reasons for diroximel fumarate in the newly initiated phase 2 FUSION study. [WATCH TIME: 3 minutes]
Latest:
Highlights of ISC 2024, Trials and Future Innovations for Stroke Care: Tudor Jovin, MD; Lauren Sansing, MD, MS, FAHAThe medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]
Latest:
Cure Rare Disease Identifies Toxicity Responsible for DMD Gene Therapy DeathCaution is warranted for older patients with Duchenne muscular dystrophy who are receiving gene therapy, according to details of a patient death in a single patient trial.
Latest:
Therapeutic Approaches to Fatigue in Multiple Sclerosis: Anna Kratz, PhDDiscussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]
Latest:
Read All About It: How On-Demand Therapy Has Changed the PD LandscapeAs therapeutic development has advanced in Parkinson disease management, the introduction of on-demand options have extended ON time for patients and altered the paradigm of care.
Latest:
Chronic Pain Treatment Options for an Aging Population in Neurology: Justin Davanzo, MDThe neurosurgeon in the department of neurology at Allegheny Health Network talked about the increasing prevalence of chronic pain as the population ages and the treatment options available to patients to provide relief. [WATCH TIME: 5 minutes]
Latest:
Challenges and Opportunities Bringing Lecanemab to Neurology Community ClinicsA group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
Latest:
Remaining Questions and Next Steps for Parkinson Agent P2B001: Lawrence Elmer, MD, PhD; Cheryl Fitzer-Attas, PhDThe medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]
Latest:
Importance of Diverse Mechanisms of Action to Effectively Treat NMOSDJacqueline Nicholas, MD MPH discusses the importance of targeting NMOSD through different mechanisms of action and highlight key points for communicating with neurologists about the role of the complement system in the disease.
Latest:
Investigating Limb Swelling in Patients With Dravet Syndrome: Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MDA trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]
Latest:
Davide Valeriani, PhD: Using the DystoniaNet Platform for Dystonia DiagnosisThe postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.
Latest:
Poor Recognition of Encephalitis in EMS Settings: Ava Easton, PhDThe chief executive at Encephalitis International talked about results from a recent survey conducted on the misconceptions of encephalitis recognition among emergency medical professionals. [WATCH TIME: 5 minutes]
Latest:
Cenobamate as a Promising Treatment for Patients With Epilepsy: William E. Rosenfeld, MD, FAAN, FAESThe neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Latest:
Managing Nonmotor Symptoms: Psychosis in Parkinson DiseasePsychosis is estimated to affect more than half of patients with Parkinson disease, and there is a growing need for improved management and therapeutic development.
